Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

RANK and RANKL

Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_633

RANK and RANKL Family Members

RANK; receptor activator of nuclear factor-κB, TNFRSF11A; tumor necrosis factor receptor superfamily, member 11a, CD265. RANKL; receptor activator of nuclear factor-κB ligand, TNFSF11; tumor necrosis factor (ligand) superfamily, member 11, OPGL; osteoprotegerin ligand, ODF; osteoclast differentiation factor, TRANCE; TNF-related activation-induced cytokine, CD254.

Historical Background

In the late 1980s, an in vitro coculture system for osteoclast formation was established. This system was shown to require cell-to-cell contact between calvarial cells and bone marrow cells for osteoclast differentiation (Suda et al. 1999). Based on this finding, it was proposed that osteoclastogenesis-supporting mesenchymal lineage cells express an osteoclast differentiation factor (ODF) in the form of a membrane-associated protein (Suda et al. 1999). In the late 1990s, the potential inhibitor of osteoclastogenesis osteoprotegerin (OPG) was cloned. OPG is a decoy receptor...

This is a preview of subscription content, log in to check access.

References

  1. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, et al. Control of mammary stem cell function by steroid hormone signalling. Nature. 2010;465:798–802.PubMedPubMedCentralGoogle Scholar
  2. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the million women study. Lancet. 2005;365:1543–51.PubMedPubMedCentralGoogle Scholar
  3. Cao Y, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV, et al. IKKa provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell. 2001;107:763–75.PubMedPubMedCentralGoogle Scholar
  4. Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell. 2002;109(Suppl):S67–79.PubMedPubMedCentralGoogle Scholar
  5. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 2000;103:41–50.PubMedPubMedCentralGoogle Scholar
  6. Fornier MN. Denosumab: second chapter in controlling bone metastases or a new book? J Clin Oncol. 2010;28:5127–31.PubMedPubMedCentralGoogle Scholar
  7. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010;468:103–7.PubMedPubMedCentralGoogle Scholar
  8. Hanada R, Leibbrandt A, Hanada T, Kitaoka S, Furuyashiki T, Fujihara H, et al. Central control of fever and female body temperature by RANKL/RANK. Nature. 2009;462:505–9.PubMedPubMedCentralGoogle Scholar
  9. Hennighausen L, Robinson GW. Information networks in the mammary gland. Nat Rev Mol Cell Biol. 2005;6:715–25.PubMedPubMedCentralGoogle Scholar
  10. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006;440:692–6.PubMedPubMedCentralGoogle Scholar
  11. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, et al. Progesterone induces adult mammary stem cell expansion. Nature. 2010;465:803–7.PubMedPubMedCentralGoogle Scholar
  12. Kadono Y, Tanaka S, Nishino J, Nishimura K, Nakamura I, Miyazaki T, et al. Rheumatoid arthritis associated with osteopetrosis. Mod Rheumatol. 2009;19:687–90.PubMedPubMedCentralGoogle Scholar
  13. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008;29:155–92.PubMedPubMedCentralGoogle Scholar
  14. Kim NS, Kim HJ, Koo BK, Kwon MC, Kim YW, Cho Y, et al. Receptor activator of NF-κB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol Cell Biol. 2006;26:1002–13.PubMedPubMedCentralGoogle Scholar
  15. Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature. 2004;428:758–63.PubMedPubMedCentralGoogle Scholar
  16. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402:304–9.PubMedPubMedCentralGoogle Scholar
  17. Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev. 2008;29:403–40.PubMedPubMedCentralGoogle Scholar
  18. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, et al. Nuclear cytokine-activated IKKa controls prostate cancer metastasis by repressing Maspin. Nature. 2007;446:690–4.PubMedPubMedCentralGoogle Scholar
  19. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821–31.PubMedPubMedCentralGoogle Scholar
  20. Miyauchi Y, Ninomiya K, Miyamoto H, Sakamoto A, Iwasaki R, Hoshi H, et al. The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J Exp Med. 2010;207:751–62.PubMedPubMedCentralGoogle Scholar
  21. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584–93.PubMedPubMedCentralGoogle Scholar
  22. Nakashima T, Takayanagi H. Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol. 2009;29:555–67.PubMedPubMedCentralGoogle Scholar
  23. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-κB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun. 2000;275:768–75.PubMedPubMedCentralGoogle Scholar
  24. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17:1231–4.PubMedPubMedCentralGoogle Scholar
  25. Nishikawa K, Nakashima T, Hayashi M, Fukunaga T, Kato S, Kodama T, et al. Blimp1-mediated repression of negative regulators is required for osteoclast differentiation. Proc Natl Acad Sci U S A. 2010;107:3117–22.PubMedPubMedCentralGoogle Scholar
  26. Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, et al. Receptor activator of NF-κB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One. 2011;6:e19234.PubMedPubMedCentralGoogle Scholar
  27. Sato K, Suematsu A, Nakashima T, Takemoto-Kimura S, Aoki K, Morishita Y, et al. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nat Med. 2006;12:1410–6.PubMedPubMedCentralGoogle Scholar
  28. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010;468:98–102.PubMedPubMedCentralGoogle Scholar
  29. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, et al. Generation of a functional mammary gland from a single stem cell. Nature. 2006;439:84–8.PubMedPubMedCentralGoogle Scholar
  30. Shinohara M, Koga T, Okamoto K, Sakaguchi S, Arai K, Yasuda H, et al. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell. 2008;132:794–806.PubMedPubMedCentralGoogle Scholar
  31. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132–9.PubMedPubMedCentralGoogle Scholar
  32. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999;20:345–57.Google Scholar
  33. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007;7:292–304.PubMedPubMedCentralGoogle Scholar
  34. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol. 2009;5:667–76.PubMedPubMedCentralGoogle Scholar
  35. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, et al. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000a;43:259–69.PubMedPubMedCentralGoogle Scholar
  36. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, et al. T cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ Nature. 2000b;408:600–5.PubMedPubMedCentralGoogle Scholar
  37. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling for terminal differentiation of osteoclasts. Dev Cell. 2002;3:889–901.PubMedPubMedCentralGoogle Scholar
  38. Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol. 2002;20:795–823.PubMedPubMedCentralGoogle Scholar
  39. Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol Rev. 2005;208:126–40.PubMedPubMedCentralGoogle Scholar
  40. Zhao B, Takami M, Yamada A, Wang X, Koga T, Hu X, et al. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat Med. 2009;15:1066–71.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Department of Cell Signaling, Graduate School of Medical and Dental SciencesTokyo Medical and Dental UniversityTokyoJapan
  2. 2.Japan Science and Technology Agency (JST), Explorative Research for Advanced Technology (ERATO) ProgramTakayanagi Osteonetwork ProjectTokyoJapan
  3. 3.Global Center of Excellence (GCOE) ProgramInternational Research Center for Molecular Science in Tooth and Bone DiseasesTokyoJapan